⌕
Climb Bio · CLYM · Nasdaq
Tenet 62 · Solid
Compare
$9.78−1.61%At closeTenet 62 · Solid
$9.78−0.16 (−1.61%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Climb Bio (CLYM) Stock

Climb Bio (CLYM) closed at $9.78 on Nov 17, 2026; its Tenet Score is 62 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

35 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$9.78
Nov 17, 2026
Market cap
$583.9M
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
1.64 – 18.33
low → high · as of close, Nov 16, 2026
Tenet Score
62/100
Solid · 340 Healthcare peers

Industry: Drugs

Climb Bio Inc. scores 62/100. Solid. Strongest on financial health and value, quality is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 62 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=340
62/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
72
Quality
20
Health
94
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueBQualityFHealthAGrowth—MomentumA+
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.6×
Sep 30, 2026 balance sheet
P/S
—
Not reported in the company's filings for this period.
ROE
−29%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
26.58
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Climb Bio Inc.

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 52 US ETFs · top wrappers by weightSee all ETFs holding CLYM →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Climb Bio in?

Climb Bio is in the Healthcare sector and the Drugs industry.

What is Climb Bio's Tenet Score?

Climb Bio's Tenet Score is 62 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.